- Cyclodextrin derivative inclusion compound for treating pancreatic cancer
-
The invention relates to a cyclodextrin derivative inclusion compound for treating the pancreatic cancer. The existing ways of two active ingredients in the inclusion compound are different, wherein gemcitabine is bonded to a beta-cyclodextrin derivative in a chemical bonding mode first, and then the beta-cyclodextrin derivative further includes erlotinib to form a drug-loaded inclusion compound.Compared with a conventional cyclodextrin inclusion compound, and the beta-cyclodextrin derivative inclusion compound can constantly release the erlotinib and the gemcitabine in the body, so that theerlotinib and the gemcitabine maintain within the effective effect concentration range in the blood for a long time. Therefore, by means of the beta-cyclodextrin derivative inclusion compound, the drug combination curative effect can be obviously improved, and an unexpected excellent effect is generated.
- -
-
-